Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BTX Stock Summary
In the News
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences:
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
Ticker Symbol to Remain “BTX” Ticker Symbol to Remain “BTX”
Brooklyn ImmunoTherapeutics Reports Inducement Grants
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on September 20, 2021, Roger Sidhu was granted a non-qualified stock option covering 161,300 shares of Brooklyn's common stock (the “Time-Based Option”) and a restricted stock unit covering 80,650 shares of Brooklyn's common stock (the “RSU”).
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021.
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience's Co-founder and Chief Executive Officer.
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
CAMBRIDGE, Mass., Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, Massachusetts, celebrated its tenth anniversary on September 9, 2021 with the grand opening of its new ISO Class 7 cleanroom facility at its headquarters near Inman Square.
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that its 2021 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held at 9 a.m., Eastern time, on August 20, 2021, was convened and adjourned, without any business being conducted, due to lack of the required quorum.
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021
NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today provided highlights from a Shareholder Update Call conducted by President and Chief Executive Officer Howard J. Federoff, M.D., Ph.D. on August 19, 2021.
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it will host a shareholder update conference call on Thursday, August 19, 2021, at 4:30 p.m. ET.
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the SNN Virtual Investor Conference being held August 17 – 19, 2021.
BTX Financial details
BTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 275.56 | 0 | 0 | 0 | 0.01 | |
Net income per share | -28.48 | 5.74 | -56.49 | -8.06 | -4.08 | |
Operating cash flow per share | 38.18 | -3.9 | -10.85 | -6.88 | -3.84 | |
Free cash flow per share | 22.96 | -3.92 | -10.92 | -6.97 | -3.84 | |
Cash per share | 45.34 | 0.79 | 7.85 | 3.75 | 1.43 | |
Book value per share | 70.83 | 3.69 | 3 | 3.97 | 0.42 | |
Tangible book value per share | 61.15 | -0.18 | -1.11 | 3.3 | 0.04 | |
Share holders equity per share | 70.83 | 3.69 | 3 | 3.97 | 0.42 | |
Interest debt per share | 88.06 | 1.42 | 1.29 | 1.37 | 1.81 | |
Market cap | 6.33M | 185.98M | 180.56M | 9.82M | 9.57M | |
Enterprise value | 9.15M | 187.25M | 166.3M | 2.52M | 43.83M | |
P/E ratio | -3.09 | 15.62 | -1.48 | -0.4 | -0.44 | |
Price to sales ratio | 0.32 | 0 | 0 | 0 | 140.66 | |
POCF ratio | 2.31 | -22.96 | -7.69 | -0.47 | -0.47 | |
PFCF ratio | 3.83 | -22.85 | -7.64 | -0.46 | -0.47 | |
P/B Ratio | 1.24 | 24.28 | 27.77 | 0.81 | 4.28 | |
PTB ratio | 1.24 | 24.28 | 27.77 | 0.81 | 4.28 | |
EV to sales | 0.46 | 0 | 0 | 0 | 644.61 | |
Enterprise value over EBITDA | 4.68 | -26.19 | 2.42 | -0.08 | -2.24 | |
EV to operating cash flow | 3.33 | -23.11 | -7.08 | -0.12 | -2.15 | |
EV to free cash flow | 5.54 | -23 | -7.03 | -0.12 | -2.15 | |
Earnings yield | -0.32 | 0.06 | -0.68 | -2.5 | -2.27 | |
Free cash flow yield | 0.26 | -0.04 | -0.13 | -2.17 | -2.14 | |
Debt to equity | 1.19 | 0.38 | 0.42 | 0.34 | 4.03 | |
Debt to assets | 0.4 | 0.22 | 0.08 | 0.19 | 0.18 | |
Net debt to EBITDA | 1.44 | -0.18 | -0.21 | 0.23 | -1.75 | |
Current ratio | 1 | 0.55 | 5.1 | 1.79 | 1.46 | |
Interest coverage | -4.87 | -168.56 | 923.54 | -1.11K | -33.67 | |
Income quality | -1.34 | 1.11 | 0.19 | 0.85 | 0.94 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.01 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 214.5 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 87.06 | |
Intangibles to total assets | 0.05 | 0.62 | 0.27 | 0.09 | 0.04 | |
Capex to operating cash flow | -0.4 | 0 | 0.01 | 0.01 | 0 | |
Capex to revenue | -0.06 | 0 | 0 | 0 | -0.28 | |
Capex to depreciation | -0.35 | -0.4 | -0.34 | -0.6 | -0.02 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 18.26 | |
Graham number | 213.05 | 21.82 | 61.78 | 26.82 | 6.21 | |
ROIC | -0.09 | 0.93 | 5.72 | -1.91 | -0.47 | |
Return on tangible assets | -0.14 | 2.44 | -5.2 | -1.21 | -0.46 | |
Graham Net | -76.31 | -1.74 | -3.89 | 0.5 | -7.34 | |
Working capital | -25K | -1.39M | 15.09M | 6.03M | 3.03M | |
Tangible asset value | 4.4M | -375K | -2.4M | 10.06M | 189K | |
Net current asset value | -4.12M | -3.52M | -7.16M | 3.51M | -37.3M | |
Invested capital | 1.19 | 0.38 | 0.42 | 0.34 | 4.03 | |
Average receivables | 0 | 597.5K | 342K | 817.5K | 688K | |
Average payables | 0 | 1.06M | 1.52M | 1.69M | 1.34M | |
Average inventory | 0 | 545K | 0 | -475.5K | -475.5K | |
Days sales outstanding | 22.02 | 0 | 0 | 0 | 2.28K | |
Days payables outstanding | 38.86 | 4.75K | 1.4K | 1.19K | 286.57 | |
Days of inventory on hand | 50.73 | 0 | 0 | -698.42 | 0 | |
Receivables turnover | 16.57 | 0 | 0 | 0 | 0.16 | |
Payables turnover | 9.39 | 0.08 | 0.26 | 0.31 | 1.27 | |
Inventory turnover | 7.2 | 0 | 0 | -0.52 | 0 | |
ROE | -0.4 | 1.55 | -18.81 | -2.03 | -9.7 | |
Capex per share | -15.22 | -0.02 | -0.07 | -0.1 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.01 | 0 | |
Net income per share | -1.24 | -1.06 | -0.85 | -1.03 | -1.14 | |
Operating cash flow per share | -1.5 | -1.18 | -0.73 | -1.08 | -0.86 | |
Free cash flow per share | -1.5 | -1.18 | -0.73 | -1.08 | -0.87 | |
Cash per share | 3.15 | 1.05 | 0.35 | 0.84 | 1.4 | |
Book value per share | 3.33 | 1.44 | 0.73 | 0.66 | 0.41 | |
Tangible book value per share | 2.77 | 1.04 | 0.34 | 0.28 | 0.03 | |
Share holders equity per share | 3.33 | 1.44 | 0.73 | 0.66 | 0.41 | |
Interest debt per share | 1.14 | 0.71 | 7.02 | 7.64 | 1.73 | |
Market cap | 11.69M | 17.43M | 11.98M | 11.79M | 9.74M | |
Enterprise value | 4.38M | 15.56M | 47.36M | 48.48M | 44.01M | |
P/E ratio | -0.65 | -0.8 | -0.66 | -0.53 | -0.4 | |
Price to sales ratio | 0 | 0 | 0 | 231.25 | 572.82 | |
POCF ratio | -2.15 | -2.88 | -3.1 | -2.02 | -2.09 | |
PFCF ratio | -2.14 | -2.88 | -3.1 | -2.02 | -2.08 | |
P/B Ratio | 0.97 | 2.36 | 3.1 | 3.31 | 4.36 | |
PTB ratio | 0.97 | 2.36 | 3.1 | 3.31 | 4.36 | |
EV to sales | 0 | 0 | 0 | 950.68 | 2.59K | |
Enterprise value over EBITDA | -0.87 | -3.02 | -12.25 | -9.72 | -8.33 | |
EV to operating cash flow | -0.81 | -2.57 | -12.23 | -8.32 | -9.44 | |
EV to free cash flow | -0.8 | -2.57 | -12.23 | -8.32 | -9.4 | |
Earnings yield | -0.38 | -0.31 | -0.38 | -0.47 | -0.63 | |
Free cash flow yield | -0.47 | -0.35 | -0.32 | -0.49 | -0.48 | |
Debt to equity | 0.34 | 0.48 | 9.63 | 11.58 | 4.03 | |
Debt to assets | 0.19 | 0.23 | 0.79 | 0.79 | 0.18 | |
Net debt to EBITDA | 1.45 | 0.36 | -9.15 | -7.36 | -6.49 | |
Current ratio | 1.79 | 1.21 | 0.54 | 0.73 | 1.46 | |
Interest coverage | -789.5 | -50.63 | 0 | -48.29 | -14.86 | |
Income quality | 1.21 | 1.12 | 0.86 | 1.04 | 0.76 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 78.02 | 265.06 | |
Research and developement to revenue | 0 | 0 | 0 | 28.57 | 71.18 | |
Intangibles to total assets | 0.09 | 0.14 | 0.04 | 0.04 | 0.04 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | -1.12 | |
Capex to depreciation | -0.24 | 0 | 0 | 0 | -0.04 | |
Stock based compensation to revenue | 0 | 0 | 0 | 3.41 | 9.71 | |
Graham number | 9.63 | 5.85 | 3.73 | 3.91 | 3.25 | |
ROIC | -0.27 | -0.45 | -0.06 | -0.07 | -0.13 | |
Return on tangible assets | -0.22 | -0.41 | -0.1 | -0.11 | -0.13 | |
Graham Net | 0.42 | -0.36 | -7.64 | -7.91 | -7.21 | |
Working capital | 6.03M | 1.11M | -3.27M | -2.6M | 3.03M | |
Tangible asset value | 10.06M | 5.34M | 1.82M | 1.52M | 189K | |
Net current asset value | 3.51M | -1.21M | -39.2M | -41.66M | -37.3M | |
Invested capital | 0.34 | 0.48 | 9.63 | 11.58 | 4.03 | |
Average receivables | 938.5K | 799K | 815.5K | 1.38M | 1.1M | |
Average payables | 1.39M | 1.54M | 2.07M | 2.07M | 1.27M | |
Average inventory | -475.5K | -475.5K | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 3.13K | 2.25K | |
Days payables outstanding | 1.7K | 2.12K | 3.82K | 1.1K | 175.56 | |
Days of inventory on hand | -995.23 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0.03 | 0.04 | |
Payables turnover | 0.05 | 0.04 | 0.02 | 0.08 | 0.51 | |
Inventory turnover | -0.09 | 0 | 0 | 0 | 0 | |
ROE | -0.37 | -0.73 | -1.17 | -1.57 | -2.76 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
BTX Frequently Asked Questions
What is Brooklyn ImmunoTherapeutics, Inc. stock symbol ?
Brooklyn ImmunoTherapeutics, Inc. is a US stock , located in Carlsbad of California and trading under the symbol BTX
What is Brooklyn ImmunoTherapeutics, Inc. stock quote today ?
Brooklyn ImmunoTherapeutics, Inc. stock price is $3.8001 today.
Is Brooklyn ImmunoTherapeutics, Inc. stock public?
Yes, Brooklyn ImmunoTherapeutics, Inc. is a publicly traded company.